Hypersomnia Research Report - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018-2020 - ResearchAndMarkets.com

September 7, 2018

DUBLIN--(BUSINESS WIRE)--Sep 7, 2018--The “Hypersomnia - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Hypersomnia - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018 report provides comprehensive insights about marketed and Phase III products for Hypersomnia. The report includes information of marketed products including their product description, patent details, forecasted sales till 2020 & API manufacturer details by country.

Coverage of API manufacturers for Hypersomnia marketed products spanning across United States, Europe, China and India. The manufacturers’ details include manufacturers’ names along with their locations.

This report provides a comprehensive understanding of the emerging Phase III therapies for Hypersomnia which can turn out to be future prospective competitors for the marketed products. It will also put light on the current market trends. Their forecasted global sales are also provided till 2020.

Key Topics Covered:

1. Report Introduction

2. Hypersomnia: Overview

Risk Factors Causes Symptoms Pathophysiology Prognosis Diagnosis Treatment

3. Comparative Analysis of Marketed and Emerging Products

4. Marketed TherapiesProduct DescriptionRoute of SynthesisMechanism of ActionPharmacologyPharmacodynamicsPharmacokineticsAdverse ReactionsClinical TrialsRegulatory MilestonesProduct Development Activities

5. Emerging Therapies (Phase III)

Product DescriptionResearch and DevelopmentProduct Development ActivitiesFor more information about this drug pipelines report visit https://www.researchandmarkets.com/research/jsxnsh/hypersomnia?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180907005440/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Central Nervous System Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/07/2018 02:31 PM/DISC: 09/07/2018 02:31 PM


Update hourly